Growing return potential in biopharmaceutical royalties, says Sagard exec

'Even in an inflationary environment, we're able to benefit from a returns perspective as a result of those prices increasing higher than we may have anticipated,' Sagard's Raja Manchanda says.

PRIVATE CREDIT

Register to unlock this content

• Daily global private credit news and market intelligence
• Expertly curated insights that keep you ahead of the market
• Faster, data-driven decision making powered by our AI interface, 'Ask PEI'
• Access to proprietary research and reports
• Selected fund performance and investor activity data

Register nowFind out more

DealsFund ManagersInvestorsSpeciality FinanceAcquisitionFund ManagersInvestors